Ligand validation:3D66

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3D66 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3D66_NAG_B_601	49%	35%	0.153	0.898	0.65	1.89	-	4	0	0	100%	0.9333
3D66_NAG_B_604	35%	39%	0.172	0.86	0.55	1.81	-	3	1	0	100%	0.9333
3D66_NAG_C_604	21%	38%	0.207	0.814	0.57	1.84	-	3	1	0	100%	0.9333
3D66_NAG_B_602	16%	37%	0.199	0.765	0.8	1.63	1	2	1	0	100%	0.9333
3D66_NAG_A_603	15%	22%	0.276	0.841	0.47	2.73	-	4	0	0	100%	0.9333
3D66_NAG_B_603	11%	42%	0.203	0.721	0.78	1.47	-	5	0	0	100%	0.9333
3D66_NAG_A_604	6%	37%	0.28	0.705	0.57	1.85	-	4	0	0	100%	0.9333
3D66_NAG_A_602	4%	29%	0.456	0.836	0.66	2.15	-	5	0	0	100%	0.9333
3D66_NAG_A_601	3%	39%	0.413	0.748	0.95	1.4	-	2	0	0	100%	0.9333
3D67_NAG_B_601	44%	34%	0.19	0.916	0.79	1.78	-	2	0	0	100%	0.9333
3D68_NAG_B_604	43%	31%	0.164	0.887	0.77	1.95	-	5	1	0	100%	0.9333
4P10_NAG_A_504	31%	27%	0.18	0.846	0.88	2.03	-	5	1	0	100%	0.9333
7NEU_NAG_A_506	24%	21%	0.133	0.759	1.25	2.02	1	5	0	0	100%	0.9333
5HVF_NAG_A_506	22%	65%	0.31	0.926	0.34	1	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333
5O59_NAG_A_601	100%	70%	0.024	0.993	0.3	0.85	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.